Author Contributions: Dr Bridge had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Bridge, Brent.
Acquisition of data: Bridge, Salary, Barbe, Birmaher, Brent.
Analysis and interpretation of data: Bridge, Iyengar, Barbe, Birmaher, Pincus, Ren, Brent.
Drafting of the manuscript: Bridge, Brent.
Critical revision of the manuscript for important intellectual content: Bridge, Iyengar, Salary, Barbe, Birmaher, Pincus, Ren, Brent.
Statistical analysis: Bridge, Iyengar, Ren, Brent.
Obtained funding: Bridge, Brent.
Administrative, technical, or material support: Bridge.
Study supervision: Birmaher, Pincus, Brent.
Financial Disclosures: Dr Bridge reports having received honoraria for an invited paper from Current Opinion in Psychiatry/Lippincott Williams & Wilkins and that from 2001-2004 he participated as a coinvestigator of an open-label trial of citalopram for treatment of pediatric recurrent abdominal pain. The study was funded by an investigator-initiated grant from Forest Labs (John V. Campo, MD, principal investigator); Dr Bridge reports having received no financial support of any kind from Forest or from Dr Campo for his participation. Salary support to Dr Bridge was provided by National Institute of Mental Health grants MH55123 and subsequently MH66371, Advanced Center for Interventions and Services Research for Early-Onset Mood and Anxiety Disorder (Dr Brent, principal investigator). Dr Birmaher reports having received royalties for publication of New Hope for Children and Teens with Bipolar Disorder from Random House Inc; and having received remuneration from the University of Cincinnati for participation in the writing of algorithms for the treatment of children with bipolar disorder (Kowatch RA, Fristad M, Birmaher B, et al. Treatment guidelines for children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry. 2005;44:213-235), sponsored by the Child and Adolescent Bipolar Foundation and supported by unrestricted educational grants from Abbott Laboratories, AstraZeneca Pharmaceuticals, Eli Lilly and Co, Forest Pharmaceuticals, Janssen Pharmaceuticals, Novartis, and Pfizer. Dr Pincus reports having served as a consultant to Bristol-Myers Squibb, Cisco Systems, Community Care Behavioral Health Organization/UPMC Health Plan, Magellan Health Care, and the Urban Institute; having received royalties for publications (none of which involved specific products) from American Psychiatric Press and Current Opinion in Psychiatry/Lippincott William and Wilkins; and having received payments for speaking from Bimark Medical Education, Comprehensive Neuroscience Inc, Medical Information Technologies, Academy of Managed Care Pharmacy (AMCP) Horizons LLC, Cardinal Health Inc, Disease Management Association of America, Institute for Health Productivity Management, and Health Partners. No other financial disclosures were reported.
Funding/Support: Dr Bridge was supported by grant K01-MH069948 from the National Institute of Mental Health (NIMH), National Institutes of Health (NIH). Dr Pincus was supported by grant 51814 from the Robert Wood Johnson Foundation and grant 1UL1RR024156-01 from the NIMH. Dr Brent was supported by grant P30-MH066371 from the NIMH.
Role of the Sponsor: The NIMH had no role in the design and conduct of the study; the collection, analysis, and interpretation of the data; or the preparation, review, or approval of the manuscript.
Additional Information:eTable 1, eTable 2, and eTable 3 are available.
Acknowledgment: We thank the following individuals for providing additional details and/or access to their respective study data: Moira Rynn, MD (Columbia University, New York, NY); Anne-Liis von Knorring, MD, PhD (University Hospital, Uppsala, Sweden); Graham J. Emslie, MD, and Taryn L. Mayes, MS (University of Texas Southwestern Medical Center, Dallas); Karen Wagner, MD, PhD (University of Texas Medical Branch, Galveston); Tarek Hammad, MD, PhD, MSc, MS, and Thomas Laughren, MD (US Food and Drug Administration, Rockville, Md); Karen A. Tourian, MD (Wyeth Research, Philadelphia, Pa); Helen Blair Simpson, MD, PhD, and Andrew B. Schmidt, CSW (Columbia University, New York, NY), Daniel A. Geller, MD (Harvard Medical School, Boston, Mass); John March, MD (Duke University Medical Center, Durham, NC); and Benedetto Vitiello, MD, Daniel Pine, MD (National Institute of Mental Health, Bethesda, Md), and John T. Walkup, MD, and Mark A. Riddle, MD (Johns Hopkins Medical Institutions, Baltimore, Md), on behalf of the Fluvoxamine Treatment of Anxiety Disorders in Children and Adolescents: Multi-center study (RUPP Anxiety Study). The RUPP Anxiety Study was conducted and supported by the NIMH and the National Center for Complementary and Alternative Medicine (NCCAM) in collaboration with the study investigators. This manuscript reflects the views of the authors and may not reflect the opinions or views of all the RUPP Anxiety Study investigators, the NIMH, or the NCCAM. We also thank Holly Irvine, BS, for support with study retrieval and data management. Ms Irvine received hourly compensation for her work; none of the other acknowledged individuals received compensation for their contributions.